Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Cash Flow: 2012-2024

Historic Net Cash Flow for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to $9.0 million.

  • Akebia Therapeutics' Net Cash Flow rose 632.35% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 1160.93%. This contributed to the annual value of $9.0 million for FY2024, which is 118.46% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Net Cash Flow of $9.0 million as of FY2024, which was up 118.46% from -$48.6 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Net Cash Flow peaked at $81.3 million during FY2020, and registered a low of -$79.3 million during FY2021.
  • In the last 3 years, Akebia Therapeutics' Net Cash Flow had a median value of -$48.6 million in 2023 and averaged -$32.8 million.
  • Per our database at Business Quant, Akebia Therapeutics' Net Cash Flow crashed by 197.50% in 2021 and then surged by 118.46% in 2024.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Net Cash Flow stood at $81.3 million in 2020, then slumped by 197.50% to -$79.3 million in 2021, then rose by 26.01% to -$58.7 million in 2022, then increased by 17.18% to -$48.6 million in 2023, then surged by 118.46% to $9.0 million in 2024.